股票 › SHTDY
国药控股 SHTDY
美股市值排名 #1939
$10.96 +$0.24 (+2.24%)
休市 · Nov 7, 5:00 pm ET
开盘$10.94
昨收$10.72
当日区间$10.92 – $10.99
成交量13.8K
市值$5.84B
市盈率（TTM）6.8
股息率4.59%
SHTDY 相关新闻
匹配 SINOPHARM GROUP CO 或代码 SHTDY 的头条新闻，按最新排序。
- Sinopharm Shares: Legal Opinion of Beijing Guofeng Law Firm Regarding the Third Extraordinary Shareholders' Meeting of Sinopharm Group Pharmaceutical Co., Ltd. for 2026
- Lazard Asset Management LLC reduced its stake in Sinopharm Group Holding (01099) by 738,800 shares at approximately HK$15.1 per share.
- FMR LLC reduced its stake in Sinopharm Group Co., Ltd. (01099) by 732,400 shares at approximately HK$15.01 per share.
- Sinopharm Modern (600420.SH): Exports of penicillin-type pharmaceutical intermediates and active pharmaceutical ingredients are primarily directed to Asian countries such as India, South Korea, and Thailand.
- JiQiang Bio: Risk Disposal Plan for Conducting Deposit, Loan, and Other Financial Services at Sinopharm Group Finance Co., Ltd.
- Jiqiang Bio: Report on the Ongoing Risk Assessment of Sinopharm Group Finance Co., Ltd.
- JiQiang Bio: Announcement Regarding the Proposed Renewal of the Financial Services Agreement with Sinopharm Group Finance Co., Ltd. and Related Party Transactions
- Sinopharm Group Co., Ltd.: 000028 Sinopharm Group Investor Relations Management Information, September 18, 2026
- Sinopharm Group (01099) elects Jin Bin as Chairman of the Board.
- Sinopharm Group (01099.HK) saw its H-share holdings increased by Lazard Asset Management LLC by 959,600 shares, valued at approximately HK$15.04 million.
- Jiuqiang Biology (300406.SZ): Plans to Renew the Financial Services Agreement with Sinopharm Group Finance Co., Ltd.
- Sinopharm Group Co., Ltd. (000028): Amid Pressure on Distribution and Retail, the Retail Business Continues to Improve
- Sinopharm Group Co., Ltd. (600511): Parent Company Demonstrates Steady Growth; H2 Growth Expected to Accelerate 正面
- Sinopharm Holdings (01099.HK): Results in line with expectations; the retail segment continues to grow rapidly.
- Sinopharm Group (01099) proposes the re-election of Lian Wanyong as an executive director of the seventh board of directors.
暂无评论——快来第一个聊聊 SHTDY。